Vjera Holthoff

Vjera Holthoff

Auto-generated profile, based on publicly available information

Vjera Holthoff

Department of Psychiatry and Psychotherapy, Dresden University of Technology, Dresden, Germany

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in NeuroImage
Verified
Journal Article
Closed access
KHK Herholz
K Herholz
ESEric Salmon
Eric Salmon
DPD Perani
D Perani
Claude BaronClaude Baron
Claude Baron
VHV Holthoff
V Holthoff
WHW D Heiss
W D Heiss

20 February 2008 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
LMLisa Mosconi
Lisa Mosconi
WTWai H. Tsui
Wai H. Tsui
KHKarl Herholz
Karl Herholz
APAlberto Pupi
Alberto Pupi
ADAlexander Drzezga
Alexander Drzezga
MLMony J. de Leon
Mony J. de Leon
This multicenter study examined 18F-FDG PET measures in the differential diagnosis of Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) from normal aging and from each other and the relation of disease-specific patterns to mild cognitive impairment (MCI). Methods: We examined the 18F-FDG PET scans of 548 subjects, including 110 healthy elderly individuals (“normals” or NLs), 114 MCI, 199 AD, 98 FTD, and 27 DLB patients, collected at 7 participating centers. Individual PET scans were Z scored using automated voxel-based comparison with generation of disease-specific patterns of cortical and hippocampal 18F-FDG uptake that were then applied to characterize MCI. Results: Standardized disease-specific PET patterns were developed that correctly classified 95% AD, 92% DLB, 94% FTD, and 94% NL. MCI patients showed primarily posterior cingulate cortex and hippocampal hypometabolism (81%), whereas neocortical abnormalities varied according to neuropsychological profiles. An AD PET pattern was observed in 79% MCI with deficits in multiple cognitive domains and 31% amnesic MCI. 18F-FDG PET heterogeneity in MCI with nonmemory deficits ranged from absent hypometabolism to FTD and DLB PET patterns. Conclusion: Standardized automated analysis of 18F-FDG PET scans may provide an objective and sensitive support to the clinical diagnosis in early dementia.

1 September 1991 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
RKR. A. Koeppe
R. A. Koeppe
VHV. A. Holthoff
V. A. Holthoff
KFK. A. Frey
K. A. Frey
MKM. R. Kilbourn
M. R. Kilbourn
DKD. E. Kuhl
D. E. Kuhl
The in vivo kinetic behavior of [11C]flumazenil ([11C]FMZ), a non-subtype-specific central benzodiazepine antagonist, is characterized using compartmental analysis with the aim of producing an optimized data acquisition protocol and tracer kinetic model configuration for the assessment of [11C]FMZ binding to benzodiazepine receptors (BZRs) in human brain. The approach presented is simple, requiring only a single radioligand injection. Dynamic positron emission tomography data were acquired on 18 normal volunteers using a 60- to 90-min sequence of scans and were analyzed with model configurations that included a three-compartment, four-parameter model, a three-compartment, three-parameter model, with a fixed value for free plus nonspecific binding; and a two-compartment, two-parameter model. Statistical analysis indicated that a four-parameter model did not yield significantly better fits than a three-parameter model. Goodness of fit was improved for three- versus two-parameter configurations in regions with low receptor density, but not in regions with moderate to high receptor density. Thus, a two-compartment, two-parameter configuration was found to adequately describe the kinetic behavior of [11C]FMZ in human brain, with stable estimates of the model parameters obtainable from as little as 20–30 min of data. Pixel-by-pixel analysis yields functional images of transport rate ( K1) and ligand distribution volume ( DV“), and thus provides independent estimates of ligand delivery and BZR binding.

28 December 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
LML. Mosconi
L. Mosconi
DPD. Perani
D. Perani
SSSandro Sorbi
Sandro Sorbi
KHK. Herholz
K. Herholz
Benedetta NacmiasBenedetta Nacmias
Benedetta Nacmias
APA. Pupi
A. Pupi
Objectives: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). Method: After 1 year, 8 of 37 patients with MCI converted to AD (22%). Differences in baseline regional glucose metabolic rate (rCMRglc) across groups were assessed on a voxel-based basis using a two-factor analysis of variance with outcome (converters [n = 8] vs nonconverters [n = 29]) and APOE genotype (E4 carriers [E4+] [n = 16] vs noncarriers [E4−] [n = 21]) as grouping factors. Results were considered significant at p < 0.05, corrected for multiple comparisons. Results: All converters showed reduced rCMRglc in the inferior parietal cortex (IPC) as compared with the nonconverters. Hypometabolism in AD-typical regions, that is, temporoparietal and posterior cingulate cortex, was found for the E4+ as compared with the E4− patients, with the E4+/converters (n = 5) having additional rCMRglc reductions within frontal areas, such as the anterior cingulate (ACC) and inferior frontal (IFC) cortex. For the whole MCI sample, IPC rCMRglc predicted conversion to AD with 84% overall diagnostic accuracy (p = 0.003). Moreover, ACC and IFC rCMRglc improved prediction for the E4+ group, yielding 100% sensitivity, 90% specificity, and 94% accuracy (p < 0.0005), thus leading to an excellent discrimination. Conclusion: Fluoro-2-deoxy-d-glucose-PET measures may improve prediction of the conversion to Alzheimer disease, especially in combination with the APOE genotype.

1 November 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
DADavide Anchisi
Davide Anchisi
BBBarbara Borroni
Barbara Borroni
MFMassimo Franceschi
Massimo Franceschi
NKNasser Kerrouche
Nasser Kerrouche
EKElke Kalbe
Elke Kalbe
DPDaniela Perani
Daniela Perani
Mild cognitive impairment (MCI) is a diagnostic entity used to describe defective memory performances that do not fulfill the criteria for dementia.1 Mild cognitive impairment includes incipient Alzheimer disease (AD) and other causes of dementia, as well as a form of cognitive impairment that does not progress to dementia and may disappear. This entity has been redefined to include amnesic MCI (aMCI) and nonamnesic MCI, according to the presence of an isolated objective memory deficit or of multiple or isolated extramemory cognitive impairment.2 This variation in MCI has been evaluated using neuroimaging3-5 and biologic markers.6,7 Results of clinical studies5,8 have suggested that neuropsychological tests, especially those evaluating delayed recall, might play an important role in identifying early or preclinical AD among subjects with MCI. These studies, however, were conducted among small groups of subjects.

1 May 2006 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Closed access
PDF file
FPFrédéric Peters
Frédéric Peters
DPDaniela Perani
Daniela Perani
KHKarl Herholz
Karl Herholz
VHVjera Holthoff
Vjera Holthoff
BBBettina Beuthien-Baumann
Bettina Beuthien-Baumann
ESEric Salmon
Eric Salmon
Orbitofrontal metabolic impairment is characteristic of the frontal variant of frontotemporal dementia (fv-FTD), as are early changes in emotional and social conduct. Two main types of behavioral disturbances have been distinguished in fv-FTD patients: apathetic and disinhibited manifestations. In this study, we searched for relationships between brain metabolism and presence of apathetic or disinhibited behavior. Metabolic activity and behavioral data were collected in 41 fv-FTD patients from European PET centers. A conjunction analysis of the PET data showed an expected impairment of metabolic activity in the anterior cingulate, ventromedial and orbital prefrontal cortex, the dorsolateral prefrontal cortex and the left anterior insula in fv-FTD subjects compared to matched controls. A correlation was observed between disinhibition scores on the Neuropsychiatric Inventory scale and a cluster of voxels located in the posterior orbitofrontal cortex (6, 28, –24). Comparison of brain activity between apathetic and nonapathetic fv-FTD patients from two centers also revealed a specific involvement of the posterior orbitofrontal cortex in apathetic subjects (4, 22, –22). The results confirm that the main cerebral metabolic impairment in fv-FTD patients affects areas specializing in emotional evaluation and demonstrate that decreased orbitofrontal activity is related to both disinhibited and apathetic syndromes in fv-FTD.